Sterling in China
This article was originally published in The Tan Sheet
Executive Summary
Joint venture with Shanghai Meiyou Pharmaceutical Company will manufacture and market Sterling's Panadol line as well as a "range of other consumer health products" in the People's Republic of China, Sterling announces Sept. 2. The U.S. firm said it will "provide manufacturing equipment and technical expertise" while Meiyou will provide "market knowledge" and "manufacturing expertise and capability." Under the agreement, Sterling will have a 60% stake in the joint venture.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning